Parse Biosciences Launches Single Cell Immune Profiling Products
2024年5月2日 - 9:15PM
ビジネスワイヤ(英語)
New single cell BCR and TCR profiling
products enable immune profiling at unprecedented scale
Parse Biosciences, a leading provider of accessible and scalable
single cell sequencing solutions, today announced the availability
of Evercode™ BCR and the expansion of its existing Evercode™ TCR
product line. The new BCR solution and updates to the existing TCR
product line expand Parse’s single cell portfolio and will enable
researchers to study the immune repertoire at unprecedented
resolution and scale.
Evercode BCR allows researchers to capture B cell receptor (BCR)
sequences together with gene expression from the same cells. While
existing tools struggle to capture the immense diversity of the BCR
repertoire, Evercode BCR offers a breakthrough by measuring paired
BCR sequences (both heavy and light chains) in up to one million
cells in a single experiment. This scalable approach enables
assignment of BCR clonotypes to various B-cell subtypes and
activation states, providing unprecedented resolution and
unleashing new capabilities in antibody discovery.
Parse has also expanded its Evercode TCR product line to enable
detection of both mouse and human TCRs and dramatically improved
performance. These updates provide improved sensitivity for both
gene expression and TCR detection and are based on the recent
release of the Version 3 chemistry for its flagship product,
Evercode Whole Transcriptome.
Both Evercode BCR and TCR are compatible with fixation, which
enables researchers to fix and store samples as they arrive and
then later batch samples together in a single experiment. This
enables time-courses and higher throughput experiments, while
minimizing any potential batch effects between samples.
“Scaling up cell counts and sample numbers are crucial for
achieving impactful results in single cell immune profiling,” said
Parse Biosciences co-founder and CTO Charlie Roco. “We are excited
about the new capabilities researchers will have with these
solutions and to provide them with the unmatched scale required to
uncover the vast repertoire diversity of the adaptive immune
system.”
Parse team members will unveil additional details about Evercode
BCR and updates to Evercode TCR at the upcoming American
Association of Immunologists (AAI) annual meeting in Chicago on
Sunday, May 5 at 10:45 AM in Exhibitor Workshop Theater #1, Hall
F1.
About Parse Biosciences
Parse Biosciences is a global life sciences company whose
mission is to accelerate progress in human health and scientific
research. Empowering researchers to perform single cell sequencing
with unprecedented scale and ease, its pioneering approach is
enabling groundbreaking discoveries in cancer treatment, tissue
repair, stem cell therapy, kidney and liver disease, brain
development, and the immune system.
Founded based on a transformative technology invented at the
University of Washington, Parse has raised over $100 million and is
used in nearly 2,000 labs across the world. Its growing portfolio
of products includes Evercode Whole Transcriptome, Evercode TCR,
Evercode BCR, CRISPR Detect, Gene Capture, and a software tool for
data analysis.
Headquartered in Seattle, Washington’s vibrant South Lake Union
district, Parse Biosciences recently opened a 34,000 square foot
headquarters and state-of-the-art laboratory.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240502001397/en/
Jay Roberts, SRPR jay@shevrushpr.com | 917.696.2142